Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AUGMENT-102: A Phase 1, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability and Preliminary Anti-Leukemic Activity of SNDX-5613 in Combination With Chemotherapy in Patients With Relapsed/Refractory Leukemias Harboring Alterations in KMT2A/MLL, Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes

X
Trial Profile

AUGMENT-102: A Phase 1, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability and Preliminary Anti-Leukemic Activity of SNDX-5613 in Combination With Chemotherapy in Patients With Relapsed/Refractory Leukemias Harboring Alterations in KMT2A/MLL, Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Daunorubicin (Primary) ; Etoposide (Primary) ; Fludarabine (Primary) ; Pegaspargase (Primary) ; Prednisone (Primary) ; Revumenib (Primary) ; Vincristine (Primary)
  • Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Acronyms AUGMENT-102
  • Sponsors Syndax Pharmaceuticals
  • Most Recent Events

    • 16 May 2024 Planned primary completion date changed from 1 Apr 2024 to 1 May 2024.
    • 27 Feb 2024 According to a Syndax Pharmaceuticals media release, additional data from this trial expected in second half of 2024.
    • 05 Jan 2024 Status changed from recruiting to active, no longer recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top